[Seven cases of gemcitabine-induced lung injury during treatment for pancreatic or biliary tract cancers]

Autor: Takehiko, Tsumura, Hiroo, Matsuo, Takanori, Maruo, Hisato, Kawakami, Kiyoaki, Hatano, Sumio, Saito, Norihiro, Nishijima, Masato, Nakatsuji, Atsuyuki, Ikeda, Hiroki, Nishikawa, Ryuichi, Kita, Yoshihiro, Okabe, Toru, Kimura, Ryoichi, Amitani, Yukio, Osaki
Rok vydání: 2009
Předmět:
Zdroj: Gan to kagaku ryoho. Cancerchemotherapy. 36(5)
ISSN: 0385-0684
Popis: Gemcitabine is an anti-cancer drug known to be safe and effective for pancreatic or biliary tract cancers, but lung injury is also known to be a rare side effect that sometimes becomes severe. Here we report seven cases of lung injury during gemcitabine treatment. Drug-induced lung injury was suspected in all cases. The male: female ratio was 5:2, and the average patient age was 71. Four had pancreatic cancers and three had biliary tract cancers. Gemcitabine had been administered an average 5.9 times at a dose of 1,141 mg. Patients showed a diffuse or patchy shadow mainly in the lower lung on computed tomography examination. Grades of adverse events were greater than 3 in all cases. Three patients died of the lung injury. Five cases had pulmonary emphysema, 2 had metastatic lung tumor as underlying pulmonary lesions, and these were assumed to have been important risk factors for drug-induced interstitial lung injury during gemcitabine treatment.
Databáze: OpenAIRE